| Business Summary | | Serono
S.A.,
headquartered
in
Geneva,
Switzerland,
is
a
global
biotechnology
company
that
has
four
recombinant
products
on
the
market:
Gonal-F,
Rebif,
Serostim,
and
Saizen.
In
addition
to
being
the
world
leader
in
reproductive
health,
Serono
has
strong
market
positions
in
the
therapeutic
fields
of
neurology,
metabolism
and
growth.
The
Company's
research
programs
are
focused
on
these
businesses
and
on
establishing
new
therapeutic
areas.
Currently,
there
are
seven
products
in
development
including
six
recombinant
proteins.
The
Company
operates
in
45
countries,
and
its
products
are
sold
in
over
100
countries. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | SRA
is
a
biotechnology
company
active
in
the
research,
development,
production
and
marketing
of
products
that
address
four
principal
therapeutic
areas:
reproductive
health,
multiple
sclerosis,
growth
and
AIDS
wasting.
For
the
six
months
ended
6/30/01,
sales
increased
13%
to
$688.9
million.
Net
income
increased
40%
to
$176.2
million.
Sales
reflect
increased
market
share.
Net
income
also
reflects
lower
cost
of
sales
as
a
percentage
of
sales. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Georges Muller | Chairman | Ernesto Bettarelli | Vice
Chairman, CEO | Jacques Theurillat | CFO | Franck Latrille | Exec.
VP | Silvaro Fumero | Sr.
Exec. VP |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|